ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "remission and rheumatoid arthritis (RA)"

  • Abstract Number: 465 • 2015 ACR/ARHP Annual Meeting

    MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort

    Mami Tamai1, Yoshikazu Nakashima1, Kazuhiko Arima2, Junko Kita1, Masataka Umeda1, Shoichi Fukui1, Ayako Nishino1, Takahisa Suzuki1, Yoshiro Horai1, Akitomo Okada3, Tomohiro Koga1, Shin-ya Kawashiri1,2, Naoki Iwamoto1, Kunihiro Ichinose1, Satoshi Yamasaki4, Hideki Nakamura1, Tomoki Origuchi5, Kiyoshi Aoyagi2, Masataka Uetani6, Katsumi Eguchi7 and Atsushi Kawakami1, 1Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 2Department of Public Health, Nagasaki University, Nagasaki, Japan, 3Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 4Hiroshima University, Hiroshima, Japan, 5Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, 6Department of Radiology and Radiation Research, Nagasaki University, Nagasaki, Japan, 7Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan

    Background/Purpose: Given the improved detection of joint injury by MRI than by clinical examination, EULAR recommendations for the use of imaging of the joints in…
  • Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting

    Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient

    KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan

    Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…
  • Abstract Number: 563 • 2015 ACR/ARHP Annual Meeting

    Abatacept Plus Methotrexate Can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis

    Paul Emery1, G Burmester2, VP Bykerk3, B Combe4, Daniel E. Furst5, M Maldonado6 and T. W. J. Huizinga7, 1University of Leeds, Leeds, United Kingdom, 2Charité – University Medicine Berlin, Berlin, Germany, 3Hospital for Special Surgery, New York, NY, 4Service d’Immuno-Rheumatologie, Montpellier, France, 5Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 6Bristol-Myers Squibb, Princeton, NJ, 7Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Assessing Very Early Rheumatoid arthritis Treatment (AVERT) was a Phase IIIb, randomized, active-controlled study to evaluate the efficacy and safety of abatacept (ABA) treatment…
  • Abstract Number: 620 • 2015 ACR/ARHP Annual Meeting

    Evaluation of Patients from the Non-Biologic Arms of Inflammatory Arthritis Clinical Trials Identifies Several Predictors of Remission, As Well As, Distinct Responder Subgroups

    Brian Tom1 and Deborah P.M. Symmons2, 1Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom, 2NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom

    Background/Purpose: The RA-MAP consortium is a UK flagship industry-academic partnership investigating clinical and biological predictors of disease outcome in patients with rheumatoid arthritis (RA). Methods:…
  • Abstract Number: 1042 • 2015 ACR/ARHP Annual Meeting

    Pragmatic Multicenter Open-Label Randomized  Controlled Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients in Remission or Stable Low Disease Activity in the Netherlands

    Marjan Ghiti Moghadam1, Harald E. Vonkeman2, Peter M. ten Klooster3, Janneke Tekstra4, Dirkjan van Schaardenburg5, Mirian Starmans-kool6,7, Elisabeth Brouwer8, Reinhard Bos9, Willem F. Lems10, Edgar Colin11, Cornelia F. Allaart12, Inger L. Meek13, Robert B.M. Landewé14, Hein J. Bernelot Moens15, Piet van Riel13, Mart A.F.J. van de Laar16, Tim Jansen17 and on behalf of the Dutch National POET Collaboration., 1rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 2Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 3Pcgr, University of Twente, Enschede, Netherlands, 4Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Jan van Breemen Research Institute, Amsterdam, Netherlands, 6Rheumatology, Orbis Medical Center, Geleen-Sittard, Netherlands, 7Rheumatology, Atrium Medical center, Heerlen, Netherlands, 8Rheumatology, University Medical center Groningen, Groningen, Netherlands, 9Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, 10Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, 11Rheumatology, Erasmus MC, Rotterdam, Netherlands, 12Department of Rheumatology, Leiden Universitary Medical Center, Leiden, Netherlands, 13Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 14Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 15rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands, 16Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 17VieCuri Medical Center, Venlo, Netherlands

    Background/Purpose: TNF-inhibitors (TNFi) are effective treatments of rheumatoid arthritis (RA). It is not clear if patients in remission or stable low disease activity need to…
  • Abstract Number: 2584 • 2015 ACR/ARHP Annual Meeting

    Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment

    Juergen Rech1, Axel J. Hueber2, Matthias Englbrecht2, Stephanie Finzel3, Judith Haschka4,5, Bernhard Manger2, Arnd Kleyer3, Michaela Reiser3, Hans-Peter Tony6, Stefan Kleinert7, Martin Feuchtenberger8, Martin Fleck9, Karin Manger10, Wolfgang Ochs11, Matthias Schmitt-Haendle12, Joerg Wendler13, Florian Schuch13, Monika Ronneberger13, Hanns-Martin Lorenz14, Hubert Nüßlein15, Rieke Alten16, Jayme Fogagnolo Cobra17, Joerg C. Henes18, Klaus Krüger19 and Georg A. Schett20, 1medical clinic 3, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 4Medical Department 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5Medical Department II, Medical University of Vienna, St. Vincent Hospital Vienna,, Vienna, Austria, 6University Hospital Würzburg, Würzburg, Germany, 7Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, 8Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, 9Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, 10Rheumatology Practice Bamberg, Bamberg, Germany, 11Rheumatologist in Private Practice, Bayreuth, Germany, 12Rheumatology Practice, Bayreuth, Germany, 13Schwerpunktpraxis Rheumatologie, Erlangen, Germany, 14University Hospital Heidelberg, Heidelberg, Germany, 15University Erlangen, Nürnberg, Germany, 16Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 17Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, 18Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, 19Praxiszentrum St. Bonifatius, München, Germany, 20University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: To analyze the role of multi-biomarker disease activity (MBDA) in predicting disease relapses in rheumatoid arthritis (RA) patients in sustained remission, tapering disease modifying…
  • Abstract Number: 2608 • 2015 ACR/ARHP Annual Meeting

    The “Rheumatoid Arthritis Impact of Disease”� Score Correlates with Other Patient Reported Outcomes and with Disease Activity Scores in Patients with RA and Its Patient Acceptable Symptom State Is More Stringent Than DAS28-Remission

    Ricardo J.O. Ferreira1,2, Cátia Duarte1,3, Sylvie Batista3, Catarina Medeiros3, J.P. Sousa3, Gisela Eugénio1, Carlos Costa1, Pedro Carvalho1, Joana F. Ferreira1, Margarida Coutinho1,4, Maria J. Salvador1,4, Laure Gossec5 and J.A.P. da Silva3,6, 1Rheumatology, Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal, 2Health Sciences Research Unit: Nursing (UICISA: E), Coimbra, Portugal, 3Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, 4Clínica Universitária de Reumatologia, Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, 5Rheumatology, Pitié Salpetriere Hospital, Paris, France, 6Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal

    Background/Purpose: The "Rheumatoid Arthritis Impact of Disease" (RAID) score is a Patient Reported Outcome (PRO) that comprises seven domains of disease[1], that may reflect the…
  • Abstract Number: 2619 • 2015 ACR/ARHP Annual Meeting

    Clinical Usefulness of Periodic Detection of Serum 14-3-3η for Predicting Efficacy of Tocilizumab in RA

    Akira Sagawa1, Takuya Isayama2, Makoto Kaneda3, Yuan Gui4, Anthony Marotta5 and Jiro Arai2, 1Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 2Medical and Biological Laboratories Co., Ltd., Ina, Japan, 3MBL Europe, Diegem, Belgium, 4Augurex Life Sciences Corp., North Vancouver, BC, Canada, 51423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada

    Background/Purpose: Serum 14-3-3η is a diagnostic marker for RA. Recent in vitro evidence indicates that it may play a casual role in the pathogenesis of…
  • Abstract Number: 2652 • 2015 ACR/ARHP Annual Meeting

    Power Doppler Ultrasound Features in Rheumatoid Arthritis Patients in Clinical Remission: Reclassifying Disease Activity?

    Facundo Vergara1, Santiago Ruta1, Maria de los Angeles Gallardo1, Emmanuel Bertiller2, Josefina Marin1, Javier Rosa3, Ricardo Garcia-Monaco4 and Enrique R. Soriano5, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 3Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, 5Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Many studies have shown disparity between clinical and ultrasound (US) findings in rheumatoid arthritis (RA). US appears to detect subclinical synovitis in patients in…
  • Abstract Number: 2654 • 2015 ACR/ARHP Annual Meeting

    The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry

    Dimitrios A. Pappas1,2, Robert J. Holt3, Ying Shan4, Jeffrey D. Kent5, John T. Nguyen4, Joel M. Kremer6 and Jeffrey D. Greenberg2,7, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3University of Illinois - Chicago, Chicago, IL, 4Corrona, LLC., Southborough, MA, 5Horizon Pharma USA, Inc., Deerfield, IL, 6Albany Medical College and The Center for Rheumatology, Albany, NY, 7NYU School of Medicine, New York, NY

    Background/Purpose: The ACR/EULAR Boolean definition of remission is expected to be used as an outcome measure in randomized clinical trials for rheumatoid arthritis (RA).  Boolean…
  • Abstract Number: 3182 • 2015 ACR/ARHP Annual Meeting

    High Body Mass Index Negatively Impacts Time to Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from a Multicenter Early Arthritis Cohort Study

    Elizabeth Schulman1, Kathleen Andersen2, Meng Zhang3, Susan M. Goodman4, Daming Lin5, Gilles Boire6, Boulos Haraoui7, Carol Hitchon8, Shahin Jamal9, Edward C. Keystone10, Janet E. Pope11, Diane Tin12, Carter Thorne13, VP Bykerk2 and CATCH Investigators, 1Rheumatology, Hospital for Special Surgey, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, 7Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9Vancouver Coastal Health, Vancouver, BC, Canada, 10Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 11University of Western Ontario, London, ON, Canada, 12The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 13Southlake Regional Health Centre, Newmarket, ON, Canada

    Background/Purpose: High BMI has been associated with worse disease severity and lower rates of sustained remission (susREM) in early rheumatoid arthritis (ERA). In this study,…
  • Abstract Number: 3183 • 2015 ACR/ARHP Annual Meeting

    The Clinical and Economic Costs of Not Achieving Remission in Rheumatoid Arthritis

    Jeffrey R. Curtis1, Lang Chen1,2, Meredith Kilgore3, Huifeng Yun4 and Jeffrey D. Greenberg5, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Bimingham, Birmingham, AL, 3Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, 4Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 5Corrona, LLC, Southborough, MA

    Background/Purpose: Treat to target guidelines recommend achieving a state of remission or low disease activity for rheumatoid arthritis (RA) patients. However, the benefit of lower…
  • Abstract Number: 434 • 2015 ACR/ARHP Annual Meeting

    Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients

    Nicole P.C. Konijn1, Lilian H.D. van Tuyl1, Maarten Boers1,2, D den Uyl1, M.M. ter Wee1, P.J.S.M. Kerstens3,4, Alexandre E. Voskuyl5, Michael T. Nurmohamed1,3, Dirkjan van Schaardenburg3,6 and Willem F. Lems1,3, 1Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, 2Epidemiology & Biostatistics, VU University medical center, Amsterdam, Netherlands, 3Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, 4Rheumatology, Westfriesgasthuis, Hoorn, Netherlands, 5Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, 6Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands

    Background/Purpose: Several sets of remission criteria have been developed. The ACR/EULAR criteria were validated against their potential to predict prognosis of rheumatoid arthritis (RA) [1].…
  • Abstract Number: 3187 • 2015 ACR/ARHP Annual Meeting

    Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population

    Bindee Kuriya1, Xiuying Li2, George A. Tomlinson3, Edward C. Keystone4, Claire Bombardier2 and OBRI Investigators, 1Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 4Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: The timing and severity of relapse and likelihood of “recapturing” remission following a relapse in RA is not well known. We aimed to describe…
  • Abstract Number: 2394 • 2014 ACR/ARHP Annual Meeting

    Sustained Remission Improves Physical Function in RA Patients Treated with Tumor Necrosis Factor Inhibitor

    Jon T. Einarsson1, Meliha C. Kapetanovic2 and Pierre Geborek3, 1Dept of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 2Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, 3Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

    Sustained Remission Improves Physical Function In RA Patients Treated with Tumor Necrosis Factor InhibitorsBackground/Purpose Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology